跳至主要内容
临床试验/NCT00567385
NCT00567385已完成4 期

An Open, Multi-centre Trial Evaluating Acceptance of the New Liquid Growth Hormone Formulation - Norditropin® SimpleXx® in Children With GH Deficiency

Novo Nordisk A/S2 个研究点 分布在 2 个国家目标入组 176 人开始时间: 2003年3月10日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
176
试验地点
2
主要终点
Assessment of acceptance

研究概览

简要总结

This trial is conducted in Europe. The aim of this trial is to evaluate the acceptance of the new liquid growth hormone formulation, somatropin, in children with growth hormone deficiency.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
3 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Growth failure due to growth hormone insufficiency (GHD)
  • Turner syndrome: established diagnosis according to sex chromosome analysis, or
  • Growth retardation in children with chronic renal disorders

排除标准

  • Pregnancy
  • Breast feeding women
  • Suspected or know allergy to trial product
  • Participating in any other trial involving other investigational products within the last 3 months
  • Previous participation in the trial
  • Other daily injection therapy (non-growth hormone, e.g insulin-therapy)

结局指标

主要结局

Assessment of acceptance

时间窗: after 12 weeks of treatment

次要结局

  • Safety
  • Adverse Events (AE)
  • Compliance

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Liquid Somatropin Formulation in Children With... | 临床试验